SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. announced that Axis’ Homocysteine European Patent Number EP0726322, which originally had very broad claims covering essentially any type of homocysteine assay, was greatly narrowed by the European Patent Office Opposition Division after hearings on October 5. The patent now will cover only homocysteine assays that use any of the following three enzymes: cystathionine ß-synthetase, betaine-homocysteine-methyltransferase, and methyl-tetrahydrofolic acid methyltransferase (methionine synthase).
